Objective:

To evaluate the efficiency of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, in improving chronic graft-versus-host disease (cGVHD) using a murine sclerodermatous cGVHD model.

Approach:

Key Findings:

• Acalabrutinib treatment improved survival and clinical cGVHD scores.
• Acalabrutinib treatment reduced skin pathology, dermal thickness, and skin fibrosis.
• In vitro studies showed that acalabrutinib inhibited mast cell activation and pro-inflammatory chemokines in a dose-dependent manner.
• Chemokine analysis revealed significant differences in serum levels of CXCL10, CXCL13, and CCL22.
• Acalabrutinib treatment decreased infiltration of B220+ cells and CD3 in the skin.
• RNA-seq analysis indicated downregulation of keratinization-associated genes with treatment.

Interpretation:

Specific inhibition of BTK with acalabrutinib may play a beneficial role in improving sclerodermatous cGVHD.

Limitations:

• Further studies are needed to assess long-term effects and potential side effects in human subjects.

Conclusion:

The study suggests that acalabrutinib could improve survival and clinical outcomes in cGVHD and warrants further investigation in patients.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.